Key Facts Surrounding This News Item
- ONS had returned 0.00% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.
More Info About Oncobiologics, Inc. (ONS)
Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in the disease areas of immunology and oncology. The company was founded in 2010 and is based in Cranbury, New Jersey. View our full ONS ticker page with ratings, news, and more.